Skip to Main Content

Once again, lawmakers are pressuring a company that sells a version of naloxone, a decades-old drug that is widely used to reverse the effect of opioid and heroin overdoses, to explain its pricing.

A group of 31 US senators — all Democrats — sent a letter on Wednesday to Kaleo seeking pricing data about its Evzio treatment, along with production costs, donation programs, and reimbursement from federal health care programs. The letter was sent after the company recently began selling a stronger version of the antidote at an even higher price than an older version that contains less medicine.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!